Early thrombolytic treatment reduces analgesic requirement in patients with myocardial infarction

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Myocardial infarction (heart attack) often necessitates significant pain management.
• The role of thrombolytic therapy in reducing pain post-myocardial infarction requires further investigation.

Purpose of the Study:

• To evaluate the impact of intravenous recombinant tissue-type plasminogen activator (rtPA) on analgesic requirements in patients with myocardial infarction.
• To compare the duration and dosage of analgesics needed in rtPA-treated patients versus placebo.

Main Methods:

• A randomized, double-blind trial involving 67 patients with myocardial infarction.
• Patients received either intravenous rtPA (100 mg) or placebo within 5 hours of symptom onset.
• Analgesic requirements were recorded over the subsequent 48 hours.

Main Results:

• Sixty-seven percent of rtPA-treated patients required less than 6 hours of analgesics, compared to 38% in the placebo group (P=0.04).
• The median morphine equivalent dose was significantly lower in the rtPA group (5.3 mg) versus the placebo group (11.2 mg) (P=0.04).

Conclusions:

• Early thrombolysis with intravenous rtPA appears to reduce the need for analgesic treatment in myocardial infarction patients.
• rtPA administration may alleviate pain associated with myocardial infarction, thereby decreasing analgesic consumption.